105
Participants
Start Date
December 31, 2007
Primary Completion Date
December 1, 2018
Study Completion Date
December 1, 2018
Sapacitabine, Arm A
200 mg b.i.d. x 7 days every 3-4 weeks
Sapacitabine, Arm B
300 mg b.i.d. x 7 days every 3 - 4 weeks
Sapacitabine, Arm C
400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks
Sapacitabine, Arm D
200 mg b.i.d. x 7 consecutive days every 4 weeks
sapacitabine, Arm E
300 mg q.d. x 7 consecutive days every 4 weeks
sapacitabine, Arm F
300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks
Sapacitabine, Arm G
200 mg b.i.d. x 7 consecutive days every 4 weeks
Sapacitabine, Arm H
300 mg q.d. x 7 consecutive days every 4 weeks
Sapacitabine, Arm I
100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks
New York Medical College, Hawthorne
Roswell Park Cancer Institiute, Buffalo
Penn State Milton S. Hershey Medical Center, Hershey
Hospital of the University of Pennsylvania, Philadelphia
Winship Cancer Institute, Atlanta
University of Alabama at Birmingham, Birmingham
Vanderbilt U Medical Center, Nashville
Northwestern University Feinberg School of Medicine, Chicago
Rush University Medical Center, Chicago
University of Chicago Cancer Research Center, Chicago
University of Nebraska Medical Center, Omaha
UCLA Division of Hematology-Oncology, Los Angeles
Stanford Hospitals and Clinics, Stanford
The Cancer Center at Hackensack University Medical Center, Hackensack
The University of Texas MD Anderson Cancer Center, Houston
Lead Sponsor
Cyclacel Pharmaceuticals, Inc.
INDUSTRY